Published by Josh White on 23rd June 2022
(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that it will develop 'GlyMab' antibodies into T-cell redirecting bispecific (TCB) antibodies, and take them into the clinic as a "promising new therapeutic approach" to treat cancer.
URL: http://www.digitallook.com/dl/news/story/32771145/...